share_log

Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock

Benzinga ·  Aug 28 20:01

14 analysts have shared their evaluations of Legend Biotech (NASDAQ:LEGN) during the recent three months, expressing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings86000
Last 30D10000
1M Ago12000
2M Ago32000
3M Ago32000

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $77.93, a high estimate of $90.00, and a low estimate of $67.00. Witnessing a positive shift, the current average has risen by 1.71% from the previous average price target of $76.62.

1724846465_0.png

Exploring Analyst Ratings: An In-Depth Overview

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment